Topical carbonic anhydrase inhibitors.

doi:10.1097/00055735-199704000-00002

Paper

Topical carbonic anhydrase inhibitors.

Published Apr 1, 1997 · D. Talluto, T. Wyse, T. Krupin

Current opinion in ophthalmology

Q1 SJR score

22

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Dorzolamide, a topically active carbonic anhydrase inhibitor, is an effective new glaucoma medication that creates a decrease in intraocular pressure similar to that produced by beta-blockers. When beta-blockers are contraindicated, dorzolamide may be used as a first-line therapy. It has excellent additivity with other topical ocular hypotensive medications, including beta-blockers and pilocarpine. Systemic side effects are minimal, particularly compared with those of oral carbonic anhydrase inhibitors. However, local side effects, including corneal edema in patients with borderline endothelial function, may occur. Decreased visual acuity and allergic reactions, which occur frequently, may curtail the use of dorzolamide in some patients.

Study Snapshot

Dorzolamide effectively reduces intraocular pressure in glaucoma patients, with minimal systemic side effects but potential local side effects.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Topical carbonic anhydrase inhibitors.

Sign up to use Study Snapshot

References

Citations